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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.

Blog Archive
► 2021 (12)
► 2020 (16)
► 2019 (19)
► 2018 (16)
► 2017 (14)
► 2016 (13)
► 2015 (24)
▼ 2014 (24)
► December (2)
► October (1)
► September (2)
► August (3)
► July (1)
► June (2)
► May (3)
► April (3)
▼ March (2)
What’s in a name? How
Huntington’s disease
gene ca...
‘It’s really getting real’:
payoffs in the effort
...
► February (3)
► January (2)
► 2013 (30)
► 2012 (26)

WEDNESDAY, MARC H 26, 2014

What’s in a name? How Huntington’s disease gene
carriers are seen by themselves and by others
In 1999 I received the results of a genetic test that showed I had 40 CAG
repeats on the huntingtin gene inherited from my mother, who died of
Huntington’s disease in 2006 after a two-decade struggle with the
disorder.
Everybody has this gene, which first appeared 800 million years ago in a
species of amoebae. Huntingtin helps our cells function properly.
The gene’s CAG repeats refer to the sequence of three nucleotide bases –
cytosine, adenine, and guanine, all building blocks of DNA – on the DNA
molecule. Most people have 27 or fewer repeats. The gene I inherited from
my father had fewer than 20.
My mother’s high CAG count caused her to start experiencing HD
symptoms – typically manifested as emotional distress, cognitive loss, and
involuntary movements – in her late forties.
The term “CAG repeats” and my mother’s count of 40 were two of the very
first facts I learned about HD after receiving news of her diagnosis in late
1995.
The geneticist used the same terminology when he revealed my test
results.
However, as he told me and many other recipients of HD test results, “a
positive test result is not a diagnosis.” While everybody with 40 or more
repeats will develop HD in his or her lifetime, scientists cannot yet predict
the exact moment and type of disease onset.
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According to John Warner, Ph.D., the director of biostatistics for CHDI
Management, Inc., which carries out the day-to-day mission of the nonprofit, HD drug-discovery biotech CHDI Foundation, Inc., 95 percent of
those individuals with 40 CAG repeats will experience disease onset
between the ages of 50 and 74. (A future article will explore the statistical
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meaning of the CAG count in greater detail.)
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With an ominous test result at age 39 but no symptoms, I needed to
construct a definition of my genetic predicament for both myself and for
others.
As I said recently in an interview, unlike treatments for certain kinds of
cancer, I cannot irradiate my defective huntingtin gene to destroy it. It’s
part of me, literally residing in every cell.
Because of its genetic nature, HD also requires a far more nuanced kind of
diagnosis. Subtle symptoms can exist for years before the more noticeable
symptoms commence.
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'Gene-positive'
For many years, I referred to myself as “gene-positive for Huntington’s
disease,” a term I heard often in HD family and scientific circles. I also
used phrases such as “tested positive for HD.”
“Gene-positive” echoed the term “HIV-positive” used by the AIDS
community. It meant not only that I had tested positive for a condition, but
that I inevitably faced its dire consequences.
Thus, “gene-positive” resonated with the deep stigma, discrimination, and
alienation suffered by members of both the AIDS and HD communities.
“Gene-positive” further implied an activist stance. As with the early years
of the fight against AIDS, we in the HD community needed to tell the
world we needed treatments and the resources to find them.
I experienced all of these feelings in the late 1990s and early 2000s, as I
immersed myself in advocacy work for the Huntington’s Disease Society of
America.
They remain with me today as we still await the discovery of an effective
treatment.
Changing perceptions
As my knowledge about HD increased, and as I came into ever closer
contact with HD researchers in labs and at events such as the annual
CHDI-sponsored HD Therapeutics Conference, both my perceptions of HD
and the terms I used to describe my situation changed.
As I learned to my first visit to CHDI in 2009, many scientists see genepositive individuals as genetically and, at least at the cellular level, even
functionally compromised from birth.
I started to hear scientists used the word “premanifest” to describe
asymptomatic, gene-positive individuals.
Soon I would be introduced to “prodrome” and “prodromal”. A precursor
or forerunner to the disease, prodrome refers to the period before onset.
However, I could never imagine using such a technical term to describe
myself to others.
Scientists and physicians also used “asymptomatic” and especially
“presymptomatic” to describe people like me. I have frequently used the
former to indicate to people that I face the danger of HD but am fine for
now.
Other phrases I have used or heard include: HD gene carrier; HD gene
mutation carrier; asymptomatic HD gene carrier; disease-gene carrier;
tested positive for the genetic defect that causes Huntington’s disease; and
carry the gene for Huntington’s disease.
Living with the ‘phantom gene’
At the World Congress on Huntington’s Disease in Rio de Janeiro last
September, HD activist, historian, and author Alice Wexler, Ph.D., noted
that much recent scientific discussion has focused on defining when HD
actually begins.
During a panel on coping with HD, Dr. Wexler asked how global HD
advocate Charles Sabine and I – both gene-positive but asymptomatic –

curehd.blogspot.com/2014/03/whats-in-name-how-huntingtons-disease.html

2/6

11/18/21, 11:27 AM

At Risk for Huntington's Disease: What’s in a name? How Huntington’s disease gene carriers are seen by themselves and by ot…

viewed ourselves as individuals living with the “phantom gene” and in
what circumstances would consider ourselves as having HD.
“It changes for me depending on where I am,” I replied. “If I’m at a
conference like this: ‘Oh, my God! I have HD.’ Because I see all these
studies and brain scans and searches for biomarkers … and references to
me as prodromal…. There’s a tendency of the scientific community to see
gene carriers as diseased from Day One.”
In settings such as my doctor’s office, I felt different, I said. “My doctor’s
telling me: this time you got a clean bill of health.”
Charles, agreeing with my outlook and saying that he “treasured” his
current good health, answered the question in a “wider, more metaphysical
sense.”
“We are not just someone who’s had a bit of bad luck,” Charles said about
having inherited the HD mutation. “We are a part of history. I have
absolutely not a single shred of doubt in my mind that, whether it’s 20, 50,
or a 100 years [off], that this disease will be managed just like HIV-AIDS
can be now.”
You can watch the entire exchange in the video below.

Living with a 'Phantom Gene': Two
Huntington's Disease Gene Carriers
Discuss Their Perceptions
from Gene Veritas

06:16

Living with a 'Phantom Gene': Two Huntington's Disease Gene Carriers
Discuss Their Perceptions from Gene Veritas on Vimeo.
A new shorthand
The latest conception emerged at the CHDI-sponsored HD therapeutics
conference in Palm Springs, CA, last month, where Andrea Varrone, M.D.,
Ph.D., of the Karolinska Institutet (Sweden) gave a presentation whose
title included the phrase “Huntington’s disease gene expansion carriers.”
That phrase very accurately describes someone like me, because it
specifically identifies the cause of the disease: an expansion of the
huntingtin gene. However, the term does not by itself identify whether a
person is symptomatic or asymptomatic.
Nevertheless, it’s good shorthand for the concept of expanded CAG
repeats.
However, both the phrase and its acronym, HDGEC, are a mouthful! They
might not resonate with the community, and even less so with the general
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public, which is more familiar with the idea of a “mutated gene” than with
the term “expanded gene.”
‘You don’t look like an HD person’
The abundance of terms to describe asymptomatic HD gene carriers
reminds me that those of us in this predicament are undergoing “the new
and harrowing human experience of living in the gray zone between a
genetic test result and the onset of a disease foretold.”
Scientists have demonstrated that changes in the brain occur ten and even
20 years before onset – meaning that my brain may already be seriously
compromised, even though I function just fine.
Inexorably, perniciously, but silently, HD attacks the brain.
However, it’s not discernible from the outside.
“You don’t look like a person who has Huntington’s disease,” a health
professional told me recently as I contemplated him writhing with pain
and discomfort from a knee operation that forced him to wear a brace and
use crutches.
There is no particular way for a premanifest person to look! Moreover, no
“crutch” yet exists to help the presymptomatic HD brain recover from the
initial assault on the cells.
As an HD gene carrier and advocate for this orphan neurological disorder,
I continually face the challenge of explaining the seriousness of the disease
and its many social implications.
Along with other neurological disease communities, we in the HD
community are still searching for the right formula to project the urgency
and significance of our predicament.
A temporary escape
Often those of us in the gray zone prefer not to deal with HD. Unlike others
in the community, we don’t yet face the minute-by-minute struggle with
symptoms.
At the local HD support group meeting this week, I was the only at-risk
individual to appear. Even so, the facilitator and her replacement-intraining for the at-risk section (which normally includes both tested and
untested asymptomatic individuals) held a session with me. I wanted to
help bring the new person up to speed on the history of the support group
and the needs of the at-risk section.
We noted that the support group’s caregiver section is usually the largest
of the three subdivisions, followed by the section for those already affected.
The at-risk is usually the smallest – even though at-risk individuals
outnumber affected individuals nationally by a ratio of at least five to one.
I sympathize completely with the occasional need to “escape” from HD, so
I understand why other at-risk people didn’t attend the meeting. However,
I am hyper-aware of the need for more individuals to participate in
research studies and clinical trials to create effective treatments.
The transition to patient status
The facilitators and I also discussed the difficult choice individuals and
facilitators must make in transitioning newly affected individuals out of
the at-risk section and into the affected section.
curehd.blogspot.com/2014/03/whats-in-name-how-huntingtons-disease.html
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I’ve witnessed this transition for a number of people. I can’t imagine how
hard it is.
Once the symptoms begin, the terminological ambiguity ends. They are
now “affected” or “symptomatic” individuals. They are “HD patients.”
I anxiously await the moment when an effective treatment would not only
ameliorate these and other patients’ symptoms, but also prevent onset in
asymptomatic gene carriers.

Posted by Gene Veritas at 8:40 PM
Labels: asymptomatic , CAG repeats , diagnosis , gene expansion carrier , genepositive , genetic test , HD gene carrier , Huntington's disease , onset , positive test
result , premanifest , presymptomatic , prodrome , tested positive

5 comments:
Anonymous said...
Thanks for sharing Gene. You're very talented and I appreciate
your insight, knowledge, and research on HD. I'm at-risk and
considering the test myself. God bless!
10:46 AM, March 27, 2014

Anonymous said...
Congratulations Gene,
That's exactly how I feel at the age of 69 with a 36 CAG count.
I'm a member of the club trying to live "as normally as
possible". Sometimes succesfully sometimes with some
questions. I know what HD means, having cared for my
beloved son Cédric who died at the age of 42. As my geneticist
says: if I live long enough I might get HD but seeing my current
condition,I have more chances to dye from something else.
How funny...
Take care gene.
Albert
2:26 AM, March 28, 2014

Anonymous said...
Hi, I read your article with great interest. My grandmother and
mother both died from HD. I have five siblings of which 2 have
been diagnosed and 2 have symptoms but have not been
diagnosed. Myself and one brother have been tested and are
negative. I have one niece that is 39 years old and has tested
positive. She does have symptoms. I lived for 37 years
wondering what my fate would be. Last August, at 55 year old, I
was tested. This is such a sad disease. I pray for a cure every
nite. Thank you for doing what you do.
12:27 PM, April 10, 2014

Nathan Provo said...
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Hi Gene. I've enjoyed following your blog over the years.
Knowing that you've posted on Isis' HD drug development
progress previously, I just wanted to quickly inform you IsisHTTRx has just been added as a preclinical stage drug on Isis'
website.
2:58 PM, April 13, 2014

Anonymous said...
Gene, your writings really mean much to me and makes my life
as a HD gene carrier easier. Thank you.
I would like to know the definition of disease onset. Is that
when the movements starts to appear or any psychiatric
symptoms?
If a person get psychiatric symptoms like anxiety at the age of
35, while the movement symptoms starts at 50, would the
registered disease onset be 35 or 50?

Take care,
Anonymous (due to health insurance)
10:48 AM, April 27, 2014
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